

Study protocol

Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A single-blind randomized controlled trial

Additional file 3: Licenses to use of copyright instruments

Bluetooth®

Dermatology Quality of Life Index (DLQI)

Lattice System Physician's Global Assessment (LS-PGA)

Data collection forms DLQI and LS-PGA

Bluetooth® product listing

The Bluetooth SIG Hereby Recognizes

Leo Pharma A/S

Member Company

D033595

Declaration ID

Referenced Qualified Design ID(s): **59305**

Listing Date: **08 December 2016**

Product Listing: **053776**

This certificate acknowledges the products declared by the member were listed in accordance with the Bluetooth® Qualification Process



This agreement, dated 28th September (the "Agreement"), is made between;

CARDIFF UNIVERSITY an institution established under royal charter with administrative offices at 30-36 Newport Road, Cardiff, CF24 0DE, United Kingdom (the "University"); and

UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED a company incorporated under the laws of England and Wales (company number 01477909) whose registered office is at 30-36 Newport Road, Cardiff CF24 0DE ("UC3"); and

University of Southern Denmark
Research Unit of Dermatology and Allergy Centre
J.B. Winsløvsvej 2C, entrance 141
DK 5000 Odense C

Together the "Parties" and each a "Party".

WHEREAS the University, through Professor A.Y. Finlay and Dr G.K. Khan have developed the Dermatology Life Quality Index, and

WHEREAS the Company wishes to use the Dermatology Life Quality Index, and

WHEREAS UC3 manages the intellectual property of Cardiff University and is willing to grant the Company a licence to use the Dermatology Life Quality Index subject to the terms and conditions hereunder.

IT is agreed as follows:

1. Definitions

Confidential Information

shall mean any knowledge, information, data or experience and any drawings, computer programmes, instructions, designs or reports thereon and copies thereof (whether technical, economic, commercial or of any other description) which is disclosed hereunder (whether orally or in writing) or which is obtained by the Party receiving Confidential Information (the Recipient) as a result of the Recipient's presence at any premises of the Party disclosing Confidential Information (the Discloser).

Different Language Version

shall mean any translation from the English version of the DLQI commissioned or confirmed by the University and available for download from <http://www.dermatology.org.uk/>

DLQI

shall mean the Dermatology Life Quality Index as developed by Professor A.Y. Finlay and Dr G.K. Khan of the University's Department of Dermatology, School of Medicine, Cardiff University, in its original form and any Different Language Version.

2. Confidentiality

- 2.1 Subject to clauses 2.3 and 2.4 below, neither UC3 nor the University will disclose to any third party any Confidential Information received from the Company, in whole or in part, or use any such Confidential Information for the benefit of the University or any third party.
- 2.2 Subject to clauses 2.3 and 2.4 below, no Party shall originate any publicity, news releases or other public announcements, written or oral, to the public, press or otherwise relating to this Agreement, to any amendment hereto, the performance hereunder or the relationship created hereby, without the other's prior written consent.
- 2.3 This confidentiality undertaking shall not apply where a Party is required to make a disclosure by a regulatory body in compliance with any law or regulation (provided that in the case of the Freedom of Information Act 2000 ("FOIA 2000") that none of the exemptions apply to the information) or the order of any court having jurisdiction over such Party and the Party being required to make such disclosure shall inform the other Parties of the requirement and notify the other Parties of the Confidential Information required to be disclosed and minimum disclosure only shall be made in order to comply with any court order and after such confidential disclosure the Confidential Information shall continue to be treated pursuant to the terms of this Agreement.
- 2.4 If the University receives a request by virtue of its status as a Public Authority under the FOIA 2000 to disclose any information, which is the subject of this Agreement then the University shall give written notice to the Company which shall respond within 10 working days of receiving such notice if the notice served by the University requires the assistance of the Company in determining whether or not an exemption under the FOIA 2000 applies to the information requested under that FOIA 2000. For the avoidance of doubt, it is hereby stated and agreed that for the purposes of any such request under the FOIA 2000, the information so requested which is subject to this Agreement shall be deemed exempt information pursuant to sections 41 and 43 of the FOIA 2000 on the grounds that it is confidential and commercially sensitive and shall be exempt from disclosure to any third party making a request under the FOIA 2000.

3. Intellectual Property and Grant of Rights

- 3.1 As consideration for the payments contemplated by clause 4 hereto, UC3 grants to the Company a non-exclusive, worldwide licence to use the DLQI for the purposes set out in Schedule 1 to this Agreement.
- 3.2 To ensure the consistency and integrity of the DLQI, the Company shall not be permitted to edit or in any way alter or amend the DLQI. In the event that the Company does edit, alter or amend the DLQI, UC3 shall have the right to terminate this Agreement with immediate effect
- 3.3 The Company shall not grant sub-licences to use the DLQI without the express written permission of UC3.
- 3.4 The Copyright Statement '© Dermatology Life Quality Index. AY Finlay, GK Khan, April 1992. www.dermatology.org.uk'. This must not be copied without the permission of the Authors' and must always be reproduced at the end of each copy of the DLQI, or visible to any user of any electronic version.

4. Payment

- 4.1 The Company shall pay to the University the sum of £7.00 GB pounds sterling or US\$11.50 for USA for each subject to whom the DLQI is administered. The number of subjects to whom the DLQI will be administered will be detailed in Schedule 1 of this Agreement. The Company will, in addition, pay VAT at the prevailing rate if applicable.
- 4.2 Payment shall fall due within thirty (30) days of the date of issue of UC3's Sterling invoice. In the event that payment is made in any currency other than pounds Sterling, UC3 reserves the right to charge any fees incurred in currency conversion.
- 4.3 All payments due under this clause 4 to UC3 shall include the reference number 2007015 and shall be paid in cleared funds to the following bank account:

Account Name:	University College Cardiff Consultants Ltd
Account Number :	70172188
Sort Code:	08 90 03
Address:	Co Operative Bank Plc, 16 17 High Street, Cardiff, CF10 1AX
Swift/Bic Code:	CPBKGB22
IBAN:	GB90 CPBK 08900370172188
Reference Number:	2007015

5. Disclaimer

- 5.1 All reasonable efforts have been made to ensure the accuracy of information and materials provided. However, the DLQI, information and advice on interpretation of the DLQI are wholly and in part provided 'as is'. Neither UC3 nor the University warrants that any of the above, where provided, are fit for any purpose or do not innocently infringe any third party intellectual property rights.
- 5.2 Save in respect of claims for death or personal injury arising from negligence by UC3 or the University, neither UC3 nor the University shall be liable for any loss or damage, howsoever caused, including but not limited to loss of profit or business, consequential loss or damages, arising from the Company's use of the DLQI or any information and advice on interpretation of the DLQI provided by the University.
- 5.3 The Company shall indemnify and hold harmless UC3 and the University from and against all claims and losses relating to the DLQI, including without limitation claims or losses howsoever arising from the supply of the DLQI to the Company by the University and/or UC3, the use of the DLQI by the Company and interpretation of data arising therefrom.

6. Support

Neither UC3 nor the University shall be under an obligation to provide any support whatsoever to the Company in the implementation of the DLQI. Any provision of support requested by the Company will be by separate agreement between UC3 and/or the University and the Company.

7. Storage of Information

The Company agrees that its contact details may be held by UC3 and the University on a secure database (in accordance with the Data Protection Act 1998) and shall be used for the purpose of administration of this licence only.

8. Duration and Termination

- 8.1 This Agreement shall take effect from the date of last signature and shall continue until the completion of the study as outlined in Schedule 1 of this Agreement. Thereafter the Parties may at their sole discretion extend this Agreement by mutual agreement in writing.
- 8.2 Any party (the "Terminating party") may terminate this Agreement by notice in writing to any of the other Parties if that other Party (the "Defaulting Party") :-

a) shall commit any material breach of this Agreement and, where such breach is capable of remedy, shall fail to remedy such breach within 30 (thirty) days after receipt of written notice from the Terminating Party requiring the breach to be remedied; or

b) becomes insolvent, or if an order is made or a resolution is passed for its winding up (other than voluntarily for the purpose of solvent amalgamation or reconstruction), or if a manager, administrator, administrative receiver or receiver is appointed in respect of the whole or any part of its assets or business, or if it makes any composition with its creditors or takes or suffers any similar or analogous action in consequence of debt in any country in the world.

- 8.3 Upon termination or expiry of this Agreement the Company shall cease to use the DLQI.
- 8.4 The termination or expiry of this Agreement howsoever arising will be without prejudice to the rights and duties of all Parties accrued prior to termination. Clauses 2.1 to 2.4 inclusive, clauses 3.1 and 3.3, clause 5.1 to 5.3 inclusive, clause 8.4, clauses 9 and 10, together with the definitions of clause 1 are expressly intended to survive termination of this Agreement.

9. Notices

Any notice required or authorised to be given hereunder shall be in writing and served personally or sent by post addressed to the relevant parties as follows:

UC3:	University College Cardiff Consultants Limited 30-36 Newport Road, Cardiff, CF24 0DE United Kingdom
------	---

For the attention of:	Dr Nick Bourne Director
-----------------------	----------------------------

The University	Cardiff University 30-36, Newport Road, CARDIFF CF24 0DE
----------------	---

For the attention of:	Mr Geraint Jones Director Research and Innovation Support
-----------------------	--

The Licensee

For the attention of:


or to such other address as may from time to time be notified to the other party hereto in writing for this purpose. Any notice served personally shall be deemed to have been given upon such service. Any notice sent by post shall be deemed to have been served five 5 days after the same shall have been posted and in proving such service it shall be sufficient to prove that the letter was properly addressed and posted.

10. Miscellaneous

- 10.1 The Parties are independent contractors and nothing in this Agreement or the performance of the parties under this Agreement shall constitute (or be deemed to constitute in law or in equity) a partnership, agency, distributorship, fiduciary, employment or joint venture relationship between the parties. The Parties are not affiliated and neither has any right or authority to bind the other in any way. Nothing in this Agreement shall be deemed to constitute any of the Parties hereto as the agent for another Party.
- 10.2 The Company may not assign its rights or delegate its responsibilities under this Agreement without the written consent of UC3 and the University.
- 10.3 If any clause or part of this Agreement is found by any court, tribunal, administrative body or authority of competent jurisdiction to be illegal, invalid or unenforceable then that provision will, to the extent required, be severed from this Agreement and will be ineffective without, as far as is possible, modifying any other clause or part of this Agreement and this will not affect any other provisions of this Agreement which will remain in full force and effect unless the substantive purpose of this Agreement is then frustrated, in which case either party may terminate this Agreement on written notice to the other.
- 10.4 No variation of this Agreement shall be valid unless it is in writing and signed by or on behalf of each of the Parties by a director or other duly authorised officer of each of the Parties.
- 10.5 No failure or delay by any Party to exercise any right, power or remedy will operate as a waiver of it nor will any partial exercise preclude any further exercise of the same, or of some other right, power or remedy.
- 10.6 This Agreement may be executed in any number of counterparts, each of which so executed will be an original, but together will constitute one and the same instrument.
- 10.7 The validity, construction and performance of this Agreement shall be governed by English law and shall be subject to the exclusive jurisdiction of the courts of England and Wales, to which the Parties to this Agreement submit.

IN WITNESS whereof the Parties have executed this Agreement by their duly authorised representatives the day and year first before written.

SIGNED by




duly authorised representative
for and on behalf of

UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD

DATE 26.09.2016

SIGNED by



duly authorised representative
for and on behalf of

CARDIFF UNIVERSITY

DATE 28.09.2016

Dr David Bembo
Acting Director
Research and Innovation Services



Mathias Tiedemann Svendsen

Trial Investigator, M.D.

University of Southern Denmark
Research Unit of Dermatology and Allergy Centre
J.B. Winsløvsvej 2C, entrance 141
DK 5000 Odense C

DATE 10.09.2016

Dermatology Life Quality Index (DLQI)

SCHEDULE I

Company Name:

University of Southern Denmark
Research Unit of Dermatology and Allergy Centre
J.B. Winsløwsvej 2C, entrance 141
DK 5000 Odense C

Company VAT Number:

DK 29283958

Study Number:

ClinicalTrials.gov identifier NCT02858713

EudraCT no. 2016-002143-42

Indication: Test if an app for Smartphones can improve medical adherence to a topical calcipotriol/betamethasone dipropionate combination. In addition, test if improved medical adherence can improve quality of life and reduce severity of psoriasis.

Number of subjects (if applicable): 128

Start Date: anticipated 01.10.2016

End Date: 31.03.2018

Languages: Danish

Total costing:

128 x £7.00 plus VAT = 896 £ plus VAT

LICENSE AGREEMENT

THIS LICENSE AGREEMENT ("Agreement"), effective as of the 2nd day of May 2016 is entered into between DATAcquire, Inc., a Michigan, USA corporation of 3929 Waldenwood, Ann Arbor, MI 48105-3008 USA (hereinafter "DATAcquire") and Department of Dermatology and Allergy Centre, Odense University Hospital of Sdr. Boulevard 29, DK-5000 Odense C (hereinafter "Licensee").

R E C I T A L S:

WHEREAS, DATAcquire has developed a scoring system for categorizing the severity of psoriasis, known as the Lattice System Physician's Global Assessment (hereinafter "LS-PGA"); and

WHEREAS, Licensee wishes to utilize LS-PGA to evaluate the effectiveness of psoriasis treatments which it may develop and for other purposes allowable under Federal and State law of the US and any countries in which Licensee will use the LS-PGA; and

WHEREAS, Licensee acknowledges that LS-PGA is a valuable scoring system which has been developed through the efforts and expense of DATAcquire and that DATAcquire owns all right, title and interest in and to LS-PGA.

NOW, THEREFORE, DATAcquire and Licensee agree as follows:

1. Upon full execution of this Agreement and receipt by DATAcquire of the consideration called for herein, DATAcquire grants to Licensee a license to use LS-PGA (whether in written, hard media, digital or other format or copies) during the term of this Agreement.
2. Title to all intellectual property rights in LS-PGA and all copies of it, including patent, trademark, copyright, and trade secret rights is and shall remain owned by DATAcquire.
3. This license is intended for use by any person employed by Licensee, but shall not be loaned, transferred or assigned to any other third party, subsidiary, joint venture partner or other party without the express written consent of DATAcquire and, if deemed appropriate by DATAcquire, without the payment of additional consideration.
4. This Agreement shall terminate immediately upon any attempt by Licensee to assign, delegate or otherwise transfer the license granted under this Agreement or to sub-license the information provided under this Agreement, without the express written consent of DATAcquire, or to otherwise violate the terms of this Agreement.
5. In exchange for the license granted in this Agreement, Licensee agrees to pay DATAcquire One Dollar US (US\$1.00) and other valuable considerations.

The license is valid for a single study, protocol, or clinical trial that incorporates the use of the LS-PGA. A new agreement shall be required for each study, protocol, or clinical trial to which Licensee assigns a separate identifying number or other indicator, or each study, protocol, or clinical trial having a separate purpose (hereinafter called a "Project"); however, each separate multicenter trial that is a Project shall require only one license regardless of the number of individual centers involved. This license is granted with the express understanding that no direct commercial support for the Project in any form is being provided to the Licensee and this license shall

terminate immediately if direct commercial support in any form is subsequently provided to the Licensee for the Project, unless subsequent written permission to continue the license is granted by DATAcquire.

6. Licensee shall notify DATAcquire of each planned use of the LS-PGA. Licensee shall use the LS-PGA as provided by DATAcquire and shall not make any changes in design, content, or wording without the written consent of DATAcquire. The copyright, patent, or other proprietary legend shall appear on all copies of LS-PGA in the same form and location as that which is provided to Licensee by DATAcquire.

7. If DATAcquire so consents in writing, Licensee may make translations and other adaptations or derivations (collectively the "Works"), and Licensee agrees to provide full and usable copies to DATAcquire. Any such Works in any form whatsoever shall constitute "works made for hire" for DATAcquire under the United States Copyright Act. To the extent that the Works do not constitute works made for hire, Licensee hereby assigns, grants, and conveys to DATAcquire all rights, titles, and interest in and to any intellectual property rights, including copyrights, patents, and trademarks, of the Works to DATAcquire. The Works are property of DATAcquire, and Licensee agrees to execute all documents necessary or desirable for DATAcquire to perfect its ownership of the Works. Appropriate copyright, patent, or other proprietary legend shall appear on all copies of the Works indicating the ownership of DATAcquire.

8. DATAcquire warrants that the LS-PGA contains the scoring system for psoriasis developed by DATAcquire in its latest form as of the date that it is provided to Licensee. DATAcquire will provide updated versions of LS-PGA upon request by Licensee, but shall have no duty to provide updates or corrections without a specific request by Licensee. DATAcquire makes no other warranties, express or implied, including warranties of merchantability or fitness for a particular purpose.

9. In no event shall DATAcquire, its officers or employees, be liable for any direct, indirect, special or consequential damages whatsoever, including, without limitation, personal injury, lost profits or loss of use with respect to any claim by Licensee or any other party on account of or arising from the use or misuse of the information or products provided under this Agreement.

10. Within fifteen (15) working days after the termination or expiration of this Agreement, Licensee shall return or destroy all original versions (and copies not in use) of the information or documents provided under this Agreement and shall certify in writing to DATAcquire that said return or destruction has been accomplished.

11. This Agreement constitutes the entire agreement between the parties, supersedes all prior agreements and understandings concerning the subject matter, and may be modified only by a writing signed by authorized representatives of both parties. If this Agreement conflicts with any purchase order submitted by Licensee, the terms of this Agreement shall prevail.

12. All notices hereunder shall be sent by certified mail to the parties at their respective addresses set forth at the beginning of this Agreement, but either party may, from time to time, send to the other party by certified mail, notice of change of address.

13. This Agreement shall have an initial term of 2 years from the date appearing at the top of page 1 and will thereafter remain in effect unless and until terminated by either party. Either party may terminate this Agreement upon thirty (30) days prior notice to the other party.

14. Each of the undersigned parties represents and warrants that it is free to enter into and fully perform this Agreement and does not now have nor shall have it entered into any contract or obligation which conflicts with any of the provisions hereof. The person signing on behalf of DATAcquire and Licensee is fully authorized to do so and shall fully bind such party to the obligations set forth in this Agreement.

15. This Agreement shall be binding upon and inure to the benefit of the parties hereto and upon their successors or assigns, and the parties hereto agree for themselves and their successors and assigns to execute any and all instruments in writing which are or may become necessary or proper to carry out the purpose and intent of this Agreement.

16. If any provision of this Agreement is held by a Court of competent jurisdiction to be invalid, void, or unenforceable, the remaining provisions nonetheless shall continue in full force without being impaired or invalidated in any way.

17. No waiver of any provisions of this Agreement shall be valid unless in writing and signed by the person or party against whom charged.


18. This Agreement may be executed in any number of counter-parts, each of which shall be taken as an original.

19. This Agreement shall be deemed for all purposes to have been drafted jointly by both of the parties with the advice of counsel, and shall not be construed for or against either party as a result of their participation or lack of participation in the preparation of this document.

20. This Agreement is being executed and delivered in the State of Michigan, USA and shall be governed by, construed and enforced in accordance with the laws of the State of Michigan, USA. The State of Michigan, USA shall be the proper venue and forum for any disputes arising hereunder.

ACCEPTED AND AGREED TO:

DATAcquire, Inc., a Michigan, USA
corporation



By: CHARLES N. ELLIS
Its: PRESIDENT

LICENSEE:

Department of Dermatology and Allergy
Centre, Odense University Hospital,
Denmark



By: Mathias Tiedemann Svendsen
Its: Principal investigator

DERMATOLOGI LIVSKVALITETSIDEKS*

Formålet med dette spørgeskema er at måle, hvor meget dit hudproblem har påvirket dit liv INDENFOR DEN SIDSTE UGE. Afkryds ☒ venligst et felt for hvert spørgsmål.

Dato for evaluering: |__| |__| |__|
Dag / Måned / År

1.	Indenfor den sidste uge, i hvor høj grad har din hud kløet, været øm, smertet eller sviet ?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	
2.	Indenfor den sidste uge, i hvor høj grad har du været fløv eller ilde til mode på grund af din hud?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	
3.	Indenfor den sidste uge, i hvor høj grad har din hud vanskeliggjort dine indkøb eller pasning af hus eller have ?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>
4.	Indenfor den sidste uge, i hvor høj grad har din hud haft indflydelse på dit valg af påklædning ?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>
5.	Indenfor den sidste uge, i hvor høj grad har din hud påvirket socialt samvær eller fritidsaktiviteter ?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>
6.	Indenfor den sidste uge, i hvor høj grad har din hud gjort det vanskeligt for dig at dyrke sport ?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>

7.	Indenfor den sidste uge, har din hud forhindret dig i at arbejde eller studere ?	Ja Nej	<input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>
	Hvis "Nej": inden for den sidste uge, i hvor høj grad har din hud været et problem for dig på arbejdet eller studiet ?	Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	
8.	Indenfor den sidste uge, i hvor høj grad har din hud skabt problemer i forbindelse med din partner , dine nære venner eller dine slægtninge ?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>
9.	Indenfor den sidste uge, i hvor høj grad har din hud forårsaget seksuelle vanskeligheder ?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>
10.	Indenfor den sidste uge, i hvor høj grad har behandlingen af din hud været et problem, for eksempel ved at dit hjem bliver rodet eller ved at optage tid?	Rigtig meget Meget Lidt Overhovedet ikke	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Ikke relevant <input type="checkbox"/>

Kontrollér venligst at du har besvaret HVERT ENKELT spørgsmål. Tak.

© A.Y. Finlay, G.K. Khan, April 1992. Ovenstående må ikke kopieres uden forfatterens tilladelse.

* Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clinical and Experimental Derm 1994; 19:210-16.

LATTICE SYSTEM PHYSICIAN'S GLOBAL ASSESSMENT (RESEARCH VERSION)

1. INDICATE PERCENT BODY SURFACE INVOLVED (do not include areas with only post-inflammatory pigmentation). *The patient's handprint (palm with fingers and thumb held together) approximate a body surface area of 1%.*

☐ 0% ☐ 1-3% ☐ 4-9% ☐ 10-20% ☐ 21-29% ☐ 30-50% ☐ 51-100%


2. CHECK ONE AND ONLY ONE BOX IN EACH ROW BELOW.
INDICATE AVERAGE QUALITIES ACROSS ALL INVOLVED AREAS.

Plaque Quality	NONE	MILD	MODERATE	MARKED
ELEVATION	<input type="checkbox"/> No elevation above normal skin <i>(Ignore scale in determining plaque elevation)</i>	<input type="checkbox"/> Slight elevation above surrounding normal skin; the edges are typically barely palpable and not seen <i>(Ignore scale in determining plaque elevation)</i>	<input type="checkbox"/> Visually apparent elevation in plaque edges; readily palpated edges with rounded or sloped edges <i>(Ignore scale in determining plaque elevation)</i>	<input type="checkbox"/> Visually obvious elevation in plaque edges; easily palpated with sharp edges that provide a discernible bump when sliding the finger from normal skin to the plaque <i>(Ignore scale in determining plaque elevation)</i>
ERYTHEMA	<input type="checkbox"/> Normal skin color or post-inflammatory color change; no erythema	<input type="checkbox"/> Pink color, including "residual hyperemia" ("end of therapy hyperemia")	<input type="checkbox"/> Light to medium red color	<input type="checkbox"/> Bright, full, or deep red color
SCALE	<input type="checkbox"/> No scales	<input type="checkbox"/> Fine scales looking like dust	<input type="checkbox"/> Individual scales discernible with yellow to silver color	<input type="checkbox"/> Coarse, thick scales, yellow to silver in color; plaque has rough surface; gives impression that scales could be lifted with fingernail

3. The above scores are combined using the separate Lattice to determine the overall LS-PGA.

Lattice System Global Psoriasis Score (LS-GPS)

Clinical Research Version



When the individual plaque qualities are used in the lattice, the most severe score that results is the final LS-GPS.